Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure
Status:
Terminated
Trial end date:
2018-02-15
Target enrollment:
Participant gender:
Summary
The study is designed to substantiate the efficacy of Cardiac Contractility Modulation (CCM)
in the heart failure population with ejection fraction ranging between 25 and 45%. The study
is designed in an adaptive manner to ensure proper statistical significance and power of the
primary efficacy evaluation.